We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock
FRTX

Delisted

FRTX was delisted on the 18th of December, 2023.

Back to rankings

27 hedge funds and large institutions have $5.87M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

4% more funds holding

Funds holding: 26 → 27 (+1)

7% less capital invested

Capital invested by funds: $6.31M → $5.87M (-$442K)

Holders
27
Holders Change
+1
Holders Change %
+3.85%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
4
Closed
1
Calls
$69K
Puts
–
Net Calls
+$69K
Net Calls Change
+$69K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$816K
2
VKH
Virtu KCG Holdings
New York
+$66.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$52.9K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$33.1K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$26.1K

Top Sellers

Rank Fund Capital Flow
1
AI
Ariel Investments
Illinois
-$277K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$187K
3
Deutsche Bank
Deutsche Bank
Germany
-$30.3K
4
AIM
Acrospire Investment Management
Illinois
-$15.5K
5
First Manhattan
First Manhattan
New York
-$705
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$1K +$705 +1 New
First Manhattan
27
First Manhattan
New York
– -$705 -1 Closed
1
2

FRTX Hedge Fund Activity: Q1 2017 in Review

27 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2017, worth a combined $5.87M — down 7% from $6.31M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new FRTX positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $816K. The largest seller was Ariel Investments, cutting an estimated $277K.

  • 27 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2017, up from 26 in Q4 2016.
  • Funds reported $5.87M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2017, down 7% quarter-over-quarter.
  • 6 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2017 and 1 closed out, a net change of +5 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $816K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2017 was Ariel Investments, an estimated $277K sold.

Based on aggregated 13F filings for Q1 2017.